JP5819578B2 - 病気に関連するタンパク質のレベルを減少させる方法 - Google Patents

病気に関連するタンパク質のレベルを減少させる方法 Download PDF

Info

Publication number
JP5819578B2
JP5819578B2 JP2008509999A JP2008509999A JP5819578B2 JP 5819578 B2 JP5819578 B2 JP 5819578B2 JP 2008509999 A JP2008509999 A JP 2008509999A JP 2008509999 A JP2008509999 A JP 2008509999A JP 5819578 B2 JP5819578 B2 JP 5819578B2
Authority
JP
Japan
Prior art keywords
protein
treatment
disease
fat
carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008509999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008542200A (ja
JP2008542200A5 (fr
Inventor
ヘンダーソン，サミュエル・ティー
Original Assignee
アクセラ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセラ・インコーポレーテッド filed Critical アクセラ・インコーポレーテッド
Publication of JP2008542200A publication Critical patent/JP2008542200A/ja
Publication of JP2008542200A5 publication Critical patent/JP2008542200A5/ja
Application granted granted Critical
Publication of JP5819578B2 publication Critical patent/JP5819578B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2008509999A 2005-05-03 2006-03-08 病気に関連するタンパク質のレベルを減少させる方法 Active JP5819578B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/123,706 US20060252775A1 (en) 2005-05-03 2005-05-03 Methods for reducing levels of disease associated proteins
US11/123,706 2005-05-03
PCT/US2006/008668 WO2006118665A2 (fr) 2005-05-03 2006-03-08 Procédé permettant de réduire les taux de protéines associées à des maladies

Publications (3)

Publication Number Publication Date
JP2008542200A JP2008542200A (ja) 2008-11-27
JP2008542200A5 JP2008542200A5 (fr) 2009-04-23
JP5819578B2 true JP5819578B2 (ja) 2015-11-24

Family

ID=37308436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008509999A Active JP5819578B2 (ja) 2005-05-03 2006-03-08 病気に関連するタンパク質のレベルを減少させる方法

Country Status (4)

Country Link
US (3) US20060252775A1 (fr)
EP (2) EP1901820A4 (fr)
JP (1) JP5819578B2 (fr)
WO (1) WO2006118665A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP1292294B1 (fr) 2000-05-01 2009-03-18 Accera, Inc. Utilisation de triglycerides de chaine moyenne pour traiter et prevenir la maladie d'alzheimer
EP2001293B9 (fr) 2006-04-03 2019-04-17 Accera, Inc. Utilisation de composés cétogènes pour le traitement des troubles cognitifs liés à l'âge
US20080089981A1 (en) * 2006-10-17 2008-04-17 N.V. Nutricia Ketogenic diet
EP2689782B1 (fr) 2007-06-26 2020-05-13 N.V. Nutricia Amélioration de la mémoire chez des sujet ayant un mini-examen de l'état mental de 24-26
WO2009002145A1 (fr) 2007-06-26 2008-12-31 N.V. Nutricia Composition lipidique destinée à améliorer l'activité cérébrale
WO2009002148A1 (fr) 2007-06-27 2008-12-31 N.V. Nutricia Composition alimentaire pour des patients à démence prodromique
WO2009002146A1 (fr) 2007-06-26 2008-12-31 N.V. Nutricia Procédé pour supporter des activités de la vie quotidienne
ES2556537T3 (es) 2007-07-31 2016-01-18 Accera, Inc. Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
RU2446807C2 (ru) 2007-12-20 2012-04-10 Н.В. Нютрисиа Жидкий продукт, содержащий нуклеотиды/нуклеозиды
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
US9125881B2 (en) * 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010093001A1 (fr) * 2009-02-13 2010-08-19 国立大学法人大阪大学 Procédé et agent de diagnostic pour la maladie d'alzheimer
WO2011074690A1 (fr) * 2009-12-14 2011-06-23 Kyoto University Composition pharmaceutique destinée à la prévention ou au traitement de la sclérose latérale amyotrophique
WO2012113415A1 (fr) * 2011-02-24 2012-08-30 N.V. Nutricia Composition pour régime cétogène pour le traitement de patients soumis à une chimiothérapie et/ou à une radiothérapie
WO2014074972A1 (fr) * 2012-11-12 2014-05-15 Nestec Sa Procédés pour déterminer si le métabolisme d'un animal est cétogène
CN105682688A (zh) * 2013-06-26 2016-06-15 雷特综合征研究信托 Rett综合征及其治疗
EP3094321B1 (fr) 2014-01-13 2019-05-01 University Of South Florida Procédés de maintien d'une cétose alimentaire et son effet sur le profil lipidique
CN107613989A (zh) * 2014-04-02 2018-01-19 南加利福尼亚大学 自身免疫病和多发性硬化症的治疗
AU2015290597B2 (en) 2014-07-17 2017-07-20 The Nisshin Oillio Group, Ltd. Baked confectionery that substantially includes no flour
WO2019013616A1 (fr) 2017-07-12 2019-01-17 N.V. Nutricia Traitement de lésion cérébrale traumatique
CN108371712B (zh) * 2018-01-18 2020-12-25 华北理工大学 咖啡因与PPARγ激动剂联合制备AD药物中的用途
JPWO2020255743A1 (fr) * 2019-06-18 2020-12-24
CN113367327B (zh) * 2021-06-03 2022-07-08 暨南大学 一种生酮饮食在预防单纯疱疹病毒性脑炎中的应用
CN113481221A (zh) * 2021-08-27 2021-10-08 黑龙江八一农垦大学 一种与奶牛酮病相关的血液中编码基因sod及其pcr检测试剂盒

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980A (en) * 1848-12-19 Machinery fob turning irbegttlab shapes
US2017520A (en) * 1929-06-20 1935-10-15 Rca Corp Glow discharge device such as is used in the recording of sound
US2766146A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US2766145A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US3053677A (en) * 1959-11-12 1962-09-11 Eastman Kodak Co Petroleum wax for paper coatings
JPS53105517A (en) * 1977-02-28 1978-09-13 Hoya Glass Works Ltd Fluorophosphate laser glass
DE2717916C3 (de) * 1977-04-22 1980-06-12 Jenaer Glaswerk Schott & Gen., 6500 Mainz Gläser mit kleiner nichtlinearer Brechzahl, insbesondere für die Lasertechnik
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
JPS55144448A (en) * 1979-04-24 1980-11-11 Nippon Kogaku Kk <Nikon> Fluorophosphate optical glass
FR2490631A1 (fr) * 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US4528197A (en) * 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4551523A (en) * 1983-04-14 1985-11-05 Eastman Kodak Company Preparation of saccharide acetoacetates
US4847296A (en) * 1984-09-13 1989-07-11 Babayan Vigen K Triglyceride preparations for the prevention of catabolism
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
US5650148A (en) * 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE3843238C1 (fr) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5412804A (en) * 1992-04-30 1995-05-02 Oracle Corporation Extending the semantics of the outer join operator for un-nesting queries to a data base
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
ES2148116T1 (es) * 1992-10-13 2000-10-16 Univ Duke Metodos de detectar la enfermedad de alzheimer.
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
US6963920B1 (en) * 1993-11-19 2005-11-08 Rose Blush Software Llc Intellectual asset protocol for defining data exchange rules and formats for universal intellectual asset documents, and systems, methods, and computer program products related to same
US5600831A (en) * 1994-02-28 1997-02-04 Lucent Technologies Inc. Apparatus and methods for retrieving information by modifying query plan based on description of information sources
US5724567A (en) * 1994-04-25 1998-03-03 Apple Computer, Inc. System for directing relevance-ranked data objects to computer users
US7049078B2 (en) * 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
JP4179641B2 (ja) * 1994-10-31 2008-11-12 株式会社住田光学ガラス Ｔｂ又はＥｕを含有するフツ燐酸塩蛍光ガラス
CA2214247C (fr) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
JP3961585B2 (ja) * 1995-11-21 2007-08-22 株式会社住田光学ガラス 可視蛍光を呈するフツ燐酸塩蛍光ガラス
KR100192233B1 (ko) * 1995-11-30 1999-06-15 구자홍 브라운관용 편향요크
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
DE19609476A1 (de) * 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
EP1006794B1 (fr) * 1997-03-12 2007-11-28 Robert W. Esmond Procede de traitement ou de prevention de la maladie d'alzheimer
CA2283642C (fr) * 1997-03-17 2012-05-15 Btg International Limited Compositions therapeutiques
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6316038B1 (en) * 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6460034B1 (en) * 1997-05-21 2002-10-01 Oracle Corporation Document knowledge base research and retrieval system
US20040058873A1 (en) 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US7152031B1 (en) * 2000-02-25 2006-12-19 Novell, Inc. Construction, manipulation, and comparison of a multi-dimensional semantic space
US6295092B1 (en) * 1998-07-30 2001-09-25 Cbs Corporation System for analyzing television programs
CN1313895A (zh) * 1998-09-14 2001-09-19 泛太平洋制药公司 蜂毒蛋白的有用特性和编码这种蜂毒蛋白的基因
US6645228B2 (en) * 2001-11-13 2003-11-11 Playtex Products, Inc. Nipple
US6711585B1 (en) * 1999-06-15 2004-03-23 Kanisa Inc. System and method for implementing a knowledge management system
US6732080B1 (en) * 1999-09-15 2004-05-04 Nokia Corporation System and method of providing personal calendar services
EP1292294B1 (fr) * 2000-05-01 2009-03-18 Accera, Inc. Utilisation de triglycerides de chaine moyenne pour traiter et prevenir la maladie d'alzheimer
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US7286977B1 (en) * 2000-09-05 2007-10-23 Novell, Inc. Intentional-stance characterization of a general content stream or repository
US7653530B2 (en) * 2000-07-13 2010-01-26 Novell, Inc. Method and mechanism for the creation, maintenance, and comparison of semantic abstracts
DE20012857U1 (de) * 2000-07-27 2000-11-09 Sportmedizin Team Vertriebs Gm Diätetisches Lebensmittel zum Fettabbau
JP4405661B2 (ja) * 2000-11-22 2010-01-27 富士通株式会社 予約サーバ，ユーザ端末及び予約システム並びに予約方法
US7117198B1 (en) * 2000-11-28 2006-10-03 Ip Capital Group, Inc. Method of researching and analyzing information contained in a database
JP2004534050A (ja) * 2001-06-07 2004-11-11 エーザイ株式会社 細胞ストレスに関連する疾病及び状態を予防及び治療する方法
US6931399B2 (en) * 2001-06-26 2005-08-16 Igougo Inc. Method and apparatus for providing personalized relevant information
US20030059824A1 (en) * 2001-09-21 2003-03-27 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
US7192897B2 (en) * 2002-07-05 2007-03-20 Hoya Corporation Near-infrared light-absorbing glass, near-infrared light-absorbing element, near-infrared light-absorbing filter, and method of manufacturing near-infrared light-absorbing formed glass article, and copper-containing glass
AU2003268235A1 (en) * 2002-09-09 2004-03-29 Mitochroma Research, Inc. Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
US6884454B2 (en) * 2002-10-21 2005-04-26 Julio Lionel Pimentel Appetite suppressing diet bar
US7103609B2 (en) * 2002-10-31 2006-09-05 International Business Machines Corporation System and method for analyzing usage patterns in information aggregates
US20040122841A1 (en) * 2002-12-19 2004-06-24 Ford Motor Company Method and system for evaluating intellectual property
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7617202B2 (en) * 2003-06-16 2009-11-10 Microsoft Corporation Systems and methods that employ a distributional analysis on a query log to improve search results
US20050013884A1 (en) * 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
WO2006007194A1 (fr) * 2004-06-25 2006-01-19 Personasearch, Inc. Processeur de recherche dynamique
US8078607B2 (en) * 2006-03-30 2011-12-13 Google Inc. Generating website profiles based on queries from webistes and user activities on the search results
DE102004038727A1 (de) * 2004-08-10 2006-02-23 Schott Ag Verfahren und Vorrichtung zum Herstellen von Hybridlinsen
JP4570576B2 (ja) * 2005-03-30 2010-10-27 Ｈｏｙａ株式会社 光学ガラス、プレス成形用プリフォームとその製造方法、および光学素子とその製造方法
JP4498315B2 (ja) * 2005-07-28 2010-07-07 Ｈｏｙａ株式会社 光学ガラスおよび光学素子とその製造方法
US7577665B2 (en) * 2005-09-14 2009-08-18 Jumptap, Inc. User characteristic influenced search results
JP5160043B2 (ja) * 2006-03-31 2013-03-13 Ｈｏｙａ株式会社 モールドプレス用ガラス素材、及びガラス光学素子の製造方法
EP2001293B9 (fr) * 2006-04-03 2019-04-17 Accera, Inc. Utilisation de composés cétogènes pour le traitement des troubles cognitifs liés à l'âge
JP5079273B2 (ja) * 2006-07-03 2012-11-21 Ｈｏｙａ株式会社 リン酸塩ガラス、フツリン酸塩ガラス、精密プレス成形用プリフォーム、光学素子およびそれぞれの製造方法
US7613692B2 (en) * 2006-07-25 2009-11-03 Microsoft Corporation Persona-based application personalization
JP2008137877A (ja) * 2006-12-05 2008-06-19 Hoya Corp 光学ガラスおよび光学素子
US10007895B2 (en) * 2007-01-30 2018-06-26 Jonathan Brian Vanasco System and method for indexing, correlating, managing, referencing and syndicating identities and relationships across systems
US8060505B2 (en) * 2007-02-13 2011-11-15 International Business Machines Corporation Methodologies and analytics tools for identifying white space opportunities in a given industry
CN106277761B (zh) * 2007-03-06 2019-09-03 Hoya株式会社 光学玻璃、模压成形用预成形件、光学元件以及它们的制造方法
US20080235189A1 (en) * 2007-03-23 2008-09-25 Drew Rayman System for searching for information based on personal interactions and presences and methods thereof
US20090063467A1 (en) * 2007-08-30 2009-03-05 Fatdoor, Inc. Persona management in a geo-spatial environment
JP5115984B2 (ja) * 2008-03-28 2013-01-09 Ｈｏｙａ株式会社 フツリン酸ガラス、プレス成形用ガラス素材、光学素子ブランク、光学素子とそれぞれの製造方法
JP5069649B2 (ja) * 2008-03-28 2012-11-07 Ｈｏｙａ株式会社 フツリン酸ガラス、精密プレス成形用プリフォーム、光学素子ブランクおよび光学素子とそれら製造方法
US8285070B2 (en) * 2008-04-07 2012-10-09 The Trustees Of Tufts College Methods and apparatus for image restoration
JP5188269B2 (ja) * 2008-05-30 2013-04-24 Ｈｏｙａ株式会社 光学ガラス、プレス成形用ガラス素材、光学素子ブランク、光学素子およびそれらの製造方法
US7870253B2 (en) * 2008-10-01 2011-01-11 The Cobalt Group, Inc. Systems and methods for aggregating user profile information in a network of affiliated websites

Also Published As

Publication number Publication date
JP2008542200A (ja) 2008-11-27
WO2006118665A3 (fr) 2008-12-18
US20100034745A1 (en) 2010-02-11
WO2006118665A2 (fr) 2006-11-09
EP1901820A4 (fr) 2012-08-29
US20060252775A1 (en) 2006-11-09
EP3124090A1 (fr) 2017-02-01
EP1901820A2 (fr) 2008-03-26
US20130005693A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
JP5819578B2 (ja) 病気に関連するタンパク質のレベルを減少させる方法
CA2392709C (fr) Composes aromatiques polyhydroxyles pour le traitement de l&#39;amylose
JP5537809B2 (ja) 脳機能を維持するための組成物及び方法
US20190388379A1 (en) Anaplerotic therapy for alzheimer&#39;s disease and the aging brain
Pettegrew et al. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression
Maalouf et al. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
Jeong et al. Intermittent fasting improves functional recovery after rat thoracic contusion spinal cord injury
US20070179197A1 (en) Compositions and methods for improving or preserving brain function
US20220110902A1 (en) Methods of treating amyloid-beta peptide diseases
AU2017277005A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
Carrie et al. PUFA for prevention and treatment of dementia?
Ouyang et al. Omega-3 fatty acids in cause, prevention and management of violence in schizophrenia: Conceptualization and application
JP5575662B2 (ja) 神経変性疾患を処置するための組成物および方法
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
Ntsapi et al. Dietary impact on neuronal autophagy control and brain health
WO2019052629A1 (fr) Lipides présentant un nombre impair d&#39;atomes de carbone et leur utilisation comme composition pharmaceutique ou complément alimentaire
Pathak Modifying Acetylation in Skeletal Muscle to Improve Health-and Life-Span
Alcover Galmes Ketogenic diets: neurodegenerative and rare diseases
Tremblay-Mercier Peroxisome Proliferator Activated Receptor Alpha (PPARα) Agonists: A Potential Tool for a Healthy Aging Brain
Lasemi The role and mechanisms of vitamin K2 in multiple sclerosis
Yu et al. Age-related changes of senescence-accelerated mouse prone 10 (SAMP10) mice as an animal model for AD
Dong et al. Neuroprotective effects of intermittent fasting in the aging brain
Mullins BT2 as a novel therapeutic compound for Alzheimer’s disease
Dolan Non-motor symptoms in the aav-α-synuclein rat model of Parkinson’s disease: exercise as a therapeutic intervention
Brownlow Diet-induced ketosis and calorie restriction in mouse models of Alzheimer's pathology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090309

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090630

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20101228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150710

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151001

R150 Certificate of patent or registration of utility model

Ref document number: 5819578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250